Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.